
|Videos|July 7, 2011
Dr. West on NSCLC Afatinib and Cetuximab Combination
Author(s)H. Jack West, MD
Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses some of the results from the phase II trial combining two therapies, afatinib and cetuximab, in patients with T790M mutated as a mechanism of resistance in non-small cell lung cancer (NSCLC). He describes that the benefit not only helped T790M patients but also those without the mutation.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
2
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
3
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
4
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
5




















































